KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.19
−1.50%2
Insider buys (3m)
4
Insider sells (3m)
-$80.3K
Net value (3m)
+1.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 20, 2026 | Tanini Annita · officer: Corp. Controller & VP, Finance | Sale | 1,224 | $10 |
| Aug 20, 2026 | Cho Esther · officer: Chief Legal Officer | Sale | 4,485 | $10 |
| Aug 20, 2026 | Lerner Lorena Raquel · officer: Chief Scientific Officer | Sale | 3,568 | $10 |
| Aug 20, 2026 | Newton Charles W. · director | Sale | 551 | $10 |
| Aug 19, 2026 | BIENAIME JEAN JACQUES · director | Purchase | 1,000 | $10 |
| Jul 17, 2026 | BIENAIME JEAN JACQUES · director | Purchase | 1,000 | $11 |
| Jul 6, 2026 | Prener Anne · director | A-Award | 13,786 | $0.00 |
| Jul 6, 2026 | Prener Anne · director | A-Award | 14,870 | $11 |
| Jun 17, 2026 | BIENAIME JEAN JACQUES · director | Purchase | 1,000 | $10 |
| Jun 15, 2026 | Newton Charles W. · director | Sale | 550 | $10 |
| Jun 8, 2026 | Farzan Nima · director | Sale | 2,625 | $11 |
| Jun 8, 2026 | Knowles Julius · director | Sale | 2,625 | $11 |
| Jun 5, 2026 | Knowles Julius · director | A-Award | 7,433 | $11 |
| Jun 5, 2026 | GRAY MARY ANN · director | A-Award | 7,433 | $11 |
| Jun 5, 2026 | BIENAIME JEAN JACQUES · director | A-Award | 7,433 | $11 |
| Jun 5, 2026 | Knowles Julius · director | A-Award | 7,142 | $0.00 |
| Jun 5, 2026 | Farzan Nima · director | A-Award | 7,142 | $0.00 |
| Jun 5, 2026 | Seth Alpna · director | A-Award | 7,433 | $11 |
| Jun 5, 2026 | Seth Alpna · director | A-Award | 7,142 | $0.00 |
| Jun 5, 2026 | Farzan Nima · director | A-Award | 7,433 | $11 |
| Jun 5, 2026 | Seth Alpna · director | Sale | 2,625 | $11 |
| Jun 5, 2026 | BIENAIME JEAN JACQUES · director | A-Award | 7,142 | $0.00 |
| Jun 5, 2026 | GRAY MARY ANN · director | A-Award | 7,142 | $0.00 |
| May 19, 2026 | BIENAIME JEAN JACQUES · director | Purchase | 1,000 | $11 |
| Apr 17, 2026 | BIENAIME JEAN JACQUES · director | Purchase | 1,000 | $12 |
| Apr 6, 2026 | Seehra Jasbir · director, officer: CHIEF EXECUTIVE OFFICER | M-Exempt | 55,000 | $0.30 |
| Mar 27, 2026 | Cho Esther · officer: Chief Legal Officer | A-Award | 80,000 | $16 |
| Mar 11, 2026 | BIENAIME JEAN JACQUES · director | Purchase | 2,000 | $11 |
| Mar 11, 2026 | Newton Charles W. · director | A-Award | 14,788 | $11 |
| Mar 11, 2026 | Newton Charles W. · director | A-Award | 13,215 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 41Increased 95Reduced 107Sold out 30
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | Increased | 2,794,217 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 2,411,793 | May 13, 2026 |
| Nantahala Capital Management, LLC | Increased | 1,410,419 | Aug 19, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Increased | 1,360,419 | May 15, 2026 |
| AQR CAPITAL MANAGEMENT LLC | Increased | 967,859 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 833,596 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 831,421 | May 15, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 759,155 | May 15, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 759,155 | Aug 14, 2026 |
| QUBE RESEARCH & TECHNOLOGIES LTD | Reduced | 724,926 | May 15, 2026 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | Reduced | 706,071 | May 15, 2026 |
| FEDERATED HERMES, INC. | Increased | 700,427 | Aug 12, 2026 |
| FEDERATED HERMES, INC. | Increased | 689,229 | May 11, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 682,043 | May 8, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 681,460 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 20, 2026